CagriSema Phase 3 clinical trials launched in China
On July 5, 2023, Pharmaceuticals observed that according to the China Drug Clinical Trial Registration and Information Disclosure Platform, Novo Nordisk has launched CagriSema phase 3 clinical trial in China. The aim is compare the safety and efficacy of CagriSema Injection with Semaglutide in obese and overweight patients.
CagriSema Injection is a long-acting combination therapy currently under research by Novo Nordisk. It consisting mainly of GLP-1 (glucagon like peptide-1) receptor agonist semaglutide and a long-acting amyloid analogue cagrilintide. CagriSema injection can be administered subcutaneously once a week.
As early as August 16, 2022, CagriSema Injection had obtained implied permission for clinical trials by CDE. Its declared indications were for weight management in adult patients with an initial body mass index (BMI) of ≥ 30 kg/m2 (obesity) or ≥ 27 kg/m2 to<30 kg/m2 (overweight) accompanied by at least one weight related comorbidities, as an adjuvant therapy to reduce calorie intake and increase physical activity.
Novo Nordisk announced that the clinical phase II experiment of CagriSema injection in diabetes patients had been successfully completed. Its weight reduction and hypoglycemic effects were better than smeglutide. In this trial, 92 type 2 diabetes patients with overweight were included, and were randomly divided into three groups. CagriSema injection (2.4mg semaglutide and 2.4mg cagrilintide), 2.4mg semaglutide alone and 2.4mg caglinitide alone. The treatment period was 32 weeks, and the average baseline HbA1c of the subjects was 8.4%, with an average baseline weight of 106kg.
Novo nordisk cagrisema clinical trials result
In terms of weight loss. CagriSema Injection had a significantly better weight loss rate of 15.6% compared to semaglutide (5.1%) and Cagrelinide (8.1%)
In terms of blood sugar reduction, CagriSema injection showed a significant decrease. It 2.18% in HbA1c compared to semaglutide (1.79%) and Cagrinide (0.93%). The proportion of HbA1c<7.0% reached 89%, with an astonishing compliance rate. Meanwhile, CagriSema injection also demonstrated good tolerability and safety characteristics.
Martin Holst Lange, executive vice president of Novo Nordisk R&D, said: “The results of the phase II trial of CagriSema in patients with type 2 diabetes are impressive and encouraging. The trial results show that CagriSema can achieve greater blood glucose reduction than semaglutide alone, and the weight loss seen in the trial confirms the substantial weight loss potential of CagriSema.”
